How to buy Aprea Therapeutics (APRE) stock

Aprea Therapeutics, Inc is a biotechnology business based in the US. Aprea Therapeutics shares (APRE) are listed on the NASDAQ and all prices are listed in US Dollars. Aprea Therapeutics employs 11 staff and has a market cap (total outstanding shares value) of 0.00.

Aprea Therapeutics stock price (NASDAQ: APRE)

Use our graph to track the performance of APRE stocks over time.

Aprea Therapeutics shares at a glance

• Key figures

Information last updated 2021-07-23.

Latest market close	$4.22
52-week range	$3.88 - $31.45
50-day moving average	$5.04
200-day moving average	$5.22
Wall St. target price	$7.25
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-22.79

Buy Aprea Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Aprea Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Aprea Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aprea Therapeutics price performance over time

Historical closes compared with the close of $4.22 from 2021-05-28

1 week (2021-07-15)	N/A
1 month (2021-06-25)	-15.94%
3 months (2021-04-26)	-12.45%
6 months (2021-01-22)	N/A

1 year (2020-07-22)	N/A
2 years (2019-07-22)	N/A
3 years (2018-07-22)	N/A
5 years (2016-07-22)	N/A

Aprea Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-31.1%
Return on equity TTM	-58.9%
Profit margin	0%
Book value	$3.26
Market capitalisation	$92.2 million

TTM: trailing 12 months

Shorting Aprea Therapeutics shares

There are currently 1.9 million Aprea Therapeutics shares held short by investors – that's known as Aprea Therapeutics's "short interest". This figure is 29.9% up from 1.5 million last month.

There are a few different ways that this level of interest in shorting Aprea Therapeutics shares can be evaluated.

Aprea Therapeutics's "short interest ratio" (SIR)

Aprea Therapeutics's "short interest ratio" (SIR) is the quantity of Aprea Therapeutics shares currently shorted divided by the average quantity of Aprea Therapeutics shares traded daily (recently around 7.3 million). Aprea Therapeutics's SIR currently stands at 0.26. In other words for every 100,000 Aprea Therapeutics shares traded daily on the market, roughly 260 shares are currently held short.

However Aprea Therapeutics's short interest can also be evaluated against the total number of Aprea Therapeutics shares, or, against the total number of tradable Aprea Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aprea Therapeutics's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Aprea Therapeutics shares in existence, roughly 90 shares are currently held short) or 0.1221% of the tradable shares (for every 100,000 tradable Aprea Therapeutics shares, roughly 122 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aprea Therapeutics.

Find out more about how you can short Aprea Therapeutics stock.

Aprea Therapeutics share dividends

We're not expecting Aprea Therapeutics to pay a dividend over the next 12 months.

Aprea Therapeutics overview

Aprea Therapeutics, Inc. , a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246 (Eprenetapopt), a small molecule p53 reactivator that is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia, as well as for relapsed/refractory TP53 mutant chronic lymphoid leukemia; and gastric, bladder, and non-small cell lung cancers. It also develops APR-548, a p53 reactivator that is on Phase I dose-escalation clinical trial for oral administration in MDS patients. The company was founded in 2006 and is headquartered in Boston, Massachusetts. .

Frequently asked questions

What percentage of Aprea Therapeutics is owned by insiders or institutions?
Currently 10.135% of Aprea Therapeutics shares are held by insiders and 52.631% by institutions. How many people work for Aprea Therapeutics?
Latest data suggests 11 work at Aprea Therapeutics. When does the fiscal year end for Aprea Therapeutics?
Aprea Therapeutics's fiscal year ends in December. Where is Aprea Therapeutics based?
Aprea Therapeutics's address is: 535 Boylston Street, Boston, MA, United States, 02116 What is Aprea Therapeutics's ISIN number?
Aprea Therapeutics's international securities identification number is: US03836J1025 What is Aprea Therapeutics's CUSIP number?
Aprea Therapeutics's Committee on Uniform Securities Identification Procedures number is: 03836J102